Jiahang Mo
Impact in
-
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
-
- Immune cells in cancer
- Phagocytosis and Immune Regulation
Papers in
- Oncology 8
- Cancer Immunotherapy and Biomarkers 4
- PARP inhibition in cancer therapy 3
-
- Immune cells in cancer 3
- Phagocytosis and Immune Regulation 2
- Co-authors
- Lihu Gu (3 shared papers)Yunfeng Jin (3 shared papers)Tong Chen (2 shared papers)Parikshit Asutosh Khadaroo (2 shared papers)Lei Dong (1 shared paper)Zefeng Shen (1 shared paper)Xiao Hu (1 shared paper)Bangsheng Chen (1 shared paper)
In The Last Decade
Jiahang Mo
15 papers receiving 265 citations
Peers
Comparison fields: 5 of 62
- Oncology 107
- Immunology 42
- Cancer Research 24
- Pulmonary and Respiratory Medicine 40
- Reproductive Medicine 9
Countries citing papers authored by Jiahang Mo
This map shows the geographic impact of Jiahang Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiahang Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiahang Mo more than expected).
Fields of papers citing papers by Jiahang Mo
This network shows the impact of papers produced by Jiahang Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiahang Mo. The network helps show where Jiahang Mo may publish in the future.
Co-authors
The 25 scholars most cited alongside Jiahang Mo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 57 | |
| 2 | 2019 | 33 | |
| 3 | 2022 | 32 | |
| 4 | 2022 | 25 | |
| 5 | 2020 | 24 | |
| 6 | 2020 | 16 | |
| 7 | 2023 | 16 | |
| 8 | 2020 | 15 | |
| 9 | 2020 | 14 | |
| 10 | 2023 | 12 | |
| 11 | 2023 | 9 | |
| 12 | 2024 | 6 | |
| 13 | 2023 | 3 | |
| 14 | 2024 | 3 | |
| 15 | 2023 | 1 | |
| 16 | 2026 | 0 |
About Jiahang Mo
Jiahang Mo is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Molecular Biology and Cell Biology, having authored 16 papers that have together received 266 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (4 papers), Immune cells in cancer (3 papers), PARP inhibition in cancer therapy (3 papers), Ferroptosis and cancer prognosis (2 papers), Endoplasmic Reticulum Stress and Disease (2 papers), Phagocytosis and Immune Regulation (2 papers), Glutathione Transferases and Polymorphisms (1 paper) and Estrogen and related hormone effects (1 paper). The work is most often cited by research in Oncology (107 citations), Immunology (42 citations), Cancer Research (24 citations), Pulmonary and Respiratory Medicine (40 citations) and Reproductive Medicine (9 citations). Jiahang Mo has collaborated with scholars based in China, Australia and Thailand. Frequent co-authors include Lihu Gu, Yunfeng Jin, Tong Chen, Parikshit Asutosh Khadaroo, Lei Dong, Zefeng Shen, Xiao Hu, Bangsheng Chen, Min Shen and Hua Jiang. Their work appears in journals such as World Journal of Surgical Oncology, BMC Cardiovascular Disorders, Frontiers in Cellular and Infection Microbiology, Critical Reviews in Oncology/Hematology and Cancer Control.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.